AUROBINDO PHARMA – Lannett Acquisition Update

1. Final regulatory hurdle cleared: Aurobindo Pharma has received clearance from the U.S. Federal Trade Commission (FTC) for its $250 million acquisition of Lannett, subject to the divestiture of four overlapping generic drug products. 2. Deal closure expected shortly: With the FTC approval now in place, the acquisition is expected to be completed within June 2026, marking a major milestone in Aurobindo’s U.S. expansion strategy. 3. Strengthens U.S. manufacturing footprint: The acquisition gives Aurobindo access to Lannett’s large manufacturing facility in Indiana, enhancing domestic U.S. production capabilities and reducing dependence on imports. 4. Strategic growth driver: Lannett brings a portfolio of generic medicines, exposure to controlled-substance therapies (including ADHD products), and a growing CDMO business, which can support revenue growth and diversification in the U.S. market. Market Impact: The development is positive for Aurobindo as it removes regulatory uncertainty around one of its largest overseas acquisitions and accelerates its U.S. manufacturing and product expansion plans. $AUROPHARMA